Before the emergence of SARS-CoV-2, the virus that causes COVID-19, influenza activity in the United States typically began to increase in the fall and peaked in February. During the 2021-22 season, influenza activity began to increase in November and remained elevated until mid-June, featuring two distinct waves, with A(H3N2) viruses predominating for the entire season. This report summarizes influenza activity during October 3, 2021-June 11, 2022, in the United States and describes the composition of the Northern Hemisphere 2022-23 influenza vaccine. Although influenza activity is decreasing and circulation during summer is typically low, remaining vigilant for influenza infections, performing testing for seasonal influenza viruses, and monitoring for novel influenza A virus infections are important. An outbreak of highly pathogenic avian influenza A(H5N1) is ongoing; health care providers and persons with exposure to sick or infected birds should remain vigilant for onset of symptoms consistent with influenza. Receiving a seasonal influenza vaccine each year remains the best way to protect against seasonal influenza and its potentially severe consequences.The United States influenza surveillance system is a collaborative effort between CDC and its many partners in state, local, and territorial health departments, public health and clinical laboratories, vital statistics offices, health care providers, hospitals, clinics, emergency departments, and long-term care facilities. This report is a summary of the 2021-22 influenza season. This report was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. †

What is a 'rapid HIV test'?This document deals with the practical and ethical implications of rapid Point of Care (POC) HIV tests using rapid test devices (RTDs). These devices deliver results within about 20 min of taking the specimen, so the results are available within a single consultation.RTDs are typically capillary flow tests for use on whole blood (e.g. finger-prick), plasma or oral fluid. They detect HIV antibodies against HIV 1 and 2 antigens produced by oligopeptide synthesis or recombinant DNA technology. They are easily read by users, and require no specialized equipment. Not all RTDs are usable at the POC (e.g. they require serum separation, but still give results in a few minutes). 'Rapid' tests are not suitable for screening large number of people.